These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17107904)

  • 1. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
    Taylor PR; White JM; Prescott RJ; Angus B; Galloway MJ; Jackson GH; Lessells AM; Lucraft HH; Summerfield GP; Proctor SJ;
    Leuk Lymphoma; 2006 Nov; 47(11):2321-30. PubMed ID: 17107904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID)--a phase II study.
    Taylor PR; Jackson GH; Galloway MJ; Soukop M; Tinegate H; Angus B; Proctor SJ
    Cancer Chemother Pharmacol; 2000; 46(1):63-8. PubMed ID: 10912580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
    Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A
    Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.
    Morra E; Gargantini L; Nosari A; Barbarano L; Pungolino E; Santoleri L; Bernuzzi P
    Crit Rev Oncol Hematol; 2000 Aug; 35(2):95-100. PubMed ID: 10936466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Pulsoni A; Gentilini P; Visani G; Perrotti A; Molinari AL; Guardigni L; Tani M; Villivà N; Stefoni V; Alinari L; Martelli M; Bonifazi F; Pileri S; Tura S; Baccarani M
    Leuk Lymphoma; 2004 Sep; 45(9):1815-9. PubMed ID: 15223641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma.
    Errante D; Sorio R; Zagonel V; Carbone A; Monfardini S; Tirelli U
    Am J Clin Oncol; 1991 Jun; 14(3):243-5. PubMed ID: 2031512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin in low-grade non-Hodgkin's lymphomas.
    Zinzani PL
    Haematologica; 1997; 82(5 Suppl):23-4. PubMed ID: 9402750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.
    Brugiatelli M; Federico M; Gobbi PG; Avanzini P; Callea V; Cavanna L; De Pasquale A; Di Prisco AU; Di Rienzo N; Silingardi V
    Haematologica; 1993; 78(5):306-12. PubMed ID: 8314160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
    Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
    Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.
    Hübel K; Tesch H; Kröger B; Schnell R; Borchmann P; Diehl V; Engert A
    Leukemia; 1997 Dec; 11 Suppl 5():S47-51. PubMed ID: 9436939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
    Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M
    Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
    J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
    Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM
    Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J
    Leuk Lymphoma; 1993; 10 Suppl():73-9. PubMed ID: 8481674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.